title: Introduction of cyclofem once-a-month injectable contraceptive in Mexico.
abstract: A large introductory study of Cyclofem, a once-a-month injectable contraceptive, was conducted in three Mexican provinces. A total of 3457 healthy women participated: 640 women from rural areas (community-based component) and 2817 women from urban and suburban areas (health center-based component). A total of 20,316 women-months of treatment experience were accumulated during a one year period. Cyclofem proved its use-effectiveness (pregnancy rate of 0.03%) and its safety under routine service conditions of family planning facilities in Mexico. The overall life table continuation rate at 1 year was 26.1%. Higher continuation rates were observed in the community-based component (36.6%) as compared to the health center component (23.7%). The most common reason for method discontinuation was change of address. Only 15% of the discontinuations were attributable to the injectable contraceptive method, with the overall 1 year discontinuation rate for bleeding problems (including amenorrhea) was < 11%. These observations underscore the importance of appropriate counseling and follow-up measures, providing convenient access to repeat injections, and other service delivery issues related to continuation of Cyclofem. The results of this trial have once again demonstrated that Cyclofem is a highly effective method with an acceptable side effect profile. In addition, the study provided the elements for its approval by local health authorities and its inclusion into the Ministry of Health Family Planning Program.
authors.affiliation: Departmento de Biologia de la Reproduccion, Instituto Nacional de la Nutricion Salvador Zubirõn, México D.F.
authors.forename: J
authors.initials: J
authors.lastname: Garza-Flores
authors.forename: A
authors.initials: A
authors.lastname: Moraks del Olmo
authors.forename: J L
authors.initials: JL
authors.lastname: Fuziwara
authors.forename: J G
authors.initials: JG
authors.lastname: Figueroa
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: J
authors.initials: J
authors.lastname: Monroy
authors.forename: M
authors.initials: M
authors.lastname: Perez
authors.forename: M
authors.initials: M
authors.lastname: Urbina-Fuentes
authors.forename: S J
authors.initials: SJ
authors.lastname: Guevara
authors.forename: E
authors.initials: E
authors.lastname: Cedeno
authors.forename: R
authors.initials: R
authors.lastname: Barrios
authors.forename: J J
authors.initials: JJ
authors.lastname: Ferman
authors.forename: L M
authors.initials: LM
authors.lastname: Medina
authors.forename: E
authors.initials: E
authors.lastname: Velazquez
authors.forename: G
authors.initials: G
authors.lastname: Perez-Palacios
mesh_terms: D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D004522:Educational Status; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D008800:Mexico; D017060:Patient Satisfaction; D011446:Prospective Studies
chemical_list: D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate